New Company Offers A.I. Aging Biomarker Analysis

(Mabel Amber, Pixabay)

15 July 2020. A new enterprise is underway using artificial intelligence to analyze a person’s body chemistry and calculate the likelihood of age-related diseases. Deep Longevity Ltd. in San Diego is spun-off from Insilico Medicine in Hong Kong, and partnering with Human Longevity Inc., a developer of genomic analytics relating to aging and an investor in the new company.

Deep Longevity plans to offer cloud-based analytical services for health care providers, insurance companies, fitness clubs, and research labs that compute a person’s biological age, a composite measure of aging computed from biomarkers, molecular indicators in a person’s body chemistry. This biological age metric is also available through apps on the company’s young.ai site and for integration in other software with an application program interface or API.

The company’s biological age provides a probability of developing age-related diseases such as diabetes, sarcopenia or loss of muscle mass, and Covid-19. Much of its A.I. technology was developed by Insilico Medicine, led Alex Zhavoronkov, founder of Insilico Medicine, and also founder and CEO of Deep Longevity. The company says its deep machine learning algorithms are trained by millions of non-identified medical records that include data from blood samples, DNA specimens, and gut microbe analysis.

“Over the past few years,” says Zhavoronkov in a Deep Longevity statement released through BusinessWire, “our team made several discoveries in the field of deep learning for longevity research in both biomarkers of aging and geroprotector discovery. Deep Longevity will translate these discoveries into the new industry of longevity management and medicine providing longevity as a service.”

Deep Longevity is collaborating with Human Longevity, also in San Diego, that provides whole genome analysis, but combines the results of that analysis with a comprehensive index of physical traits to offer personalized insights into an individual’s health. The company says its analytics can lead to better health planning and more treatment options for extending a person’s lifetime. In October 2016, Science & Enterprise reported on a team from Human Longevity that performed an in-depth sequencing of more than 10,000 human genomes, revealing 150 million new or uncommon genetic variations.

“The longevity industry is rapidly evolving and is likely to become the largest industry on the planet,” says Wei-Wu He, executive chairman of Human Longevity, who adds, “One of the main breakthroughs of the past decade is the invention of the so-called aging clocks, biomarkers of aging that allow us to measure the rate of aging and evaluate the effectiveness of the various interventions.”

Deep Longevity is raising funds in its first venture financing round, although dollar amounts were not disclosed. Leading the round are Human Longevity, ETP Ventures, and Performance Impact Venture Fund. Taking part in the financing are BOLD Capital Partners, Longevity Vision Fund, LongeVC, and Oculus co-founder Michael Antonov. The company says other undisclosed investors from artificial intelligence and biotechnology businesses are also taking part.

More from Science & Enterprise:

• Antibody Drug Biotech Raises $105M in Venture Funds
• Covid-19 Therapies Designed with Virtual Reality, A.I.
• FDA Analyzing Real-World Evidence on Covid-19
• Symptom App, Algorithm Predict Covid-19 Infections
• A.I.-Aided Method Predicts Glaucoma Progression

*     *     *